- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05831033
Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients With Advanced Solid Tumors
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Jianhua Chen, Doctor
- Phone Number: +86 17321168230
- Email: jianhuachen15@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 201620
- Shanghai General Hospital
-
Contact:
- Jianhua Chen, Doctor
- Phone Number: +86 17321168230
- Email: jianhuachen15@163.com
-
Shanghai, Shanghai, China, 200125
- Renji Hospital
-
Contact:
- Wenjing Wang, Master
- Phone Number: +86 18964874021
- Email: wenjingwang2@126.com
-
Contact:
- Wen Kong, Doctor
- Phone Number: +8613585982964
- Email: kongwen@renji.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion criteria
- Be able and willing to provide written informed consent, and to comply with all requirements of study participation (including all study procedures).
- Age: 18 - 70 years.
- Histological or cytological diagnosis of advanced metastatic solid tumors.
- Progression on standard therapy, or intolerance to, refusal or unable to benefit from standard therapy according to investigator's judgement.
- At least one resectable lesion (or aggregate of lesions) of a minimum 15 mm in diameter post-resection; or core biopsy (aggregate of around 1 gram or two 18G puncture needles).
- At least one measurable target lesion, as defined by RECIST v1.1.Lesions in previously irradiated areas (or other local therapy) should not be selected as target lesions, unless treatment was ≥ 3 months prior to screening, and there has been demonstrated disease progression in that particular lesion.
- ECOG performance status of 0 or 1.
- Life expectancy of at least 3 months.
Adequate organ and marrow function (hematology, renal, hepatic and coagulation).
- Absolute neutrophil count (ANC) ≥ 1.0×10^9/L.
- Hemoglobin (Hb) ≥ 80 g/L.
- Platelet ≥ 75×10^9/L.
- Sufficient coagulation: APPT<40 and INR<1,5.
- Creatinine clearance (CrCL) ≥45 mL/min or serum creatinine ≤1.5mg/dL was estimated using the Cockcroft-Gault formula.
- Serum alanine transaminase (ALT)/ serum glutamic-pyruvic transaminase (SGPT) and aspartate transaminase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) ≤ 3 times the upper limit of normal (ULN); patients with liver metastasis ≤ 5 times ULN.
- Estimated creatinine clearance (eCrCl) ≥ 40 mL/min using the Cockcroft-Gault formula.
- Total bilirubin ≤ 1.5 times ULN.
- Patients with Gilbert's syndrome must have a total bilirubin ≤ 1.5 times ULN.
- Patients with left ventricular ejection fraction (LVEF) ≥50% or New York Heart Association (NYHA) functional classification ≤ Class 1.
- Patients with pulmonary function test (forced expiratory volume in 1 second FEV1) ≥75%.
Exclusion criteria
- Patients who have received an organ allograft or prior cell transfer therapy.
- Patients who have a history of hypersensitivity to any component or excipient of study drugs.
- Patients who have active central nervous system (CNS) metastases(except stable brain metastases without hormone dependence or drug treatment within 3 months before enrollment).
- Patients who have active medical illness(es) that would pose increased risk for study participation, including: active systemic infections requiring systemic antibiotic therapy, coagulation disorders, or other active major medical illnesses of the cardiovascular, respiratory, or immune system.
- Active hepatitis C subjects (Hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive), human immunodeficiency virus (HIV) antibody positive; syphilis primary screening antibody positive; untreated active hepatitis B subjects (hepatitis B surface antigen (HBsAg) positive, or hepatitis B core antibody (HBcAb) positive and peripheral blood HBV DNA quantitative test greater than ULN), hepatitis B subjects need to receive anti-HBV treatment during the study period.
- Previous history of immunodeficiency (any form, primary or acquired), current long-term use of systemic corticosteroids or other immunosuppressants. Patients receiving steroids as replacement therapy for adrenocortical insufficiency at ≤ 10 mg/day of prednisone or other steroid equivalent may be eligible.
- Patients who have had another primary malignancy within the previous 3 years (with the exception of carcinoma in situ of the breast, cervix, or bladder; localized prostate cancer; and non-melanoma skin cancer that has been adequately treated).
- Patients who have received a live or attenuated vaccine within 28 days before signing the informed consent.
- Received other cell therapy products in the past.
- History of Grade ≥3 immune mediated AE (including AST/ALT elevations that where considered drug related and cytokine release syndrome) that was considered related to prior immune modulatory therapy (eg, immune checkpoint inhibitors, co-stimulatory agents, etc.) and required immunosuppressive therapy.
- Patients who are pregnant or breastfeeding.
- Before enrollment, adverse event due to any previous treatment or surgery which had not recovered to ≤ Grade 1 (according to CTCAE V5.0); except: alopecia, peripheral neuropathy ≤ grade 2, events that remain stable during supportive therapy (such as stable hypothyroidism with hormone replacement therapy), or other events that have no safety risk as assessed by the investigator.
- Patients who do not consent to the use of medically approved contraceptive methods during the study.
- Patients whose cancer requires immediate attention or who in the investigator's judgement is not suitable to participate in this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BEN101
BEN101 infusion single dose level between 1x10^9 to 1x 10^11,not lower than 1×10^9 cells, final dose is affected by the starting amount of TILs cells isolated from the tumor tissue sample.
|
Lymphodepletion regimen:Cyclophosphamide 250mg/ m2/day x 3 days (day -4, -3,-2) , Fludarabine 25mg/ m2/day x 2 days (day-4, -3) , Paclitaxel 100mg/ m2/day -3. The lymphodepletion regimen could be adjusted by the treating physician according to patient's disease condition. BEN101 infusion: Single dose level between 1x10^9 to 1x 10^11,not lower than 1×10^9 cells, final dose is affected by the starting amount of TILs cells isolated from the tumor tissue sample. IL-2:Administer 8-16 hr after TIL infusion. 600,000 IU/kg intravenously over 15-20 mins every 12 hours. It is recommended to start with high dose; and de-escalate based on tolerability, up to 5 days. IL-2 administration will be terminated if unacceptable toxicities occur. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events (AE)
Time Frame: 6 month
|
Adverse events according to CTCAE v5.0, Treatment Emergent Adverse event (TEAE) >=grade 3; Treatment related adverse event (TRAE).
|
6 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Up to 24 months
|
Proportion of patients with response to evaluate efficacy parameters such as Objective Response Rate (ORR) using RECIST v1.1 as assessed by the Investigator
|
Up to 24 months
|
Disease Control Rate (DCR)
Time Frame: Up to 24 months
|
Proportion of patients with response per response to evaluate efficacy parameters such as Disease Control Rate (DCR) using RECIST v1.1 as assessed by the Investigator
|
Up to 24 months
|
Duration of response (DOR)
Time Frame: Up to 24 months
|
To evaluate efficacy parameters such as Duration of Response (DOR) using RECIST v1.1 as assessed by the Investigator
|
Up to 24 months
|
Progression free survival (PFS)
Time Frame: Up to 24 months
|
The time length between BEN101 infusion and confirmed subsequent disease progression according to RECIST 1.1
|
Up to 24 months
|
Overall survival (OS)
Time Frame: Up to 24 months
|
The length of time from the date of the start of BEN101 treatment that the patients are still alive
|
Up to 24 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Hongxia Wang, Doctor, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Principal Investigator: Wen Di, Doctor, Renji Hospital
- Principal Investigator: Wei Xue, Doctor, Renji Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 101T1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China